ENSYSCE BIOSCIENCES, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
ENSYSCE BIOSCIENCES, INC. (ENSC) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $25.73 thousand as of 2024-03-31, per its 10-Q filed 2024-05-13.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2025-03-10
- 2024-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $25.73K.
- 2023-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.20M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2024-03-31 | $25.73K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $1.20M 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |